RenovoRx, Inc. (RNXT) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon. I will be your conference call operator today. Please note that today's call is being recorded and all participants, other than management, are in a listen-only mode. There will be a Q&A session following management's presentation. I will now turn the call over to Walter Pinto, Managing Director of KCSA Strategic Communications. Please go ahead. Thank you, Operator. Good afternoon, everyone, and welcome to the Renovo REC's first quarter 2026 earnings conference call. I'm joined today by members of our leadership team, including Dr. Ramtan Agha, Chief Medical Officer and Executive Chair, Sean Begay, Chief Executive Officer, and Mark Voll, Chief Financial Officer. Before we begin, I'd like to remind everyone that statements made during today's conference call contain or may contain forward-looking statements covered by the safe harbor provisions of the Private Security Litigation Reform Act of 1995 and applicable federal securities laws. These statements, including statements regarding Renovo Rx's clinical and commercial plans, strategies, and estimates or expectations of financial results, including revenue and operational performance, are based on management's current plans and assumptions, and actual results may differ materially. Please refer to our filings with the SEC, including our form 10Q, for the quarter ended March 31st, 2026, for a detailed discussion of the risks and uncertainties facing Renovo RX. With that, I'd like to turn the call over to our Chief Executive Officer, Sean Begay. Thank you, Walter, and good afternoon, everyone. When we spoke with you in late March, we told you that Q1 2026 would be our strongest revenue quarter yet. Today, I am pleased to confirm that we delivered on that commitment. Our first quarter results mark an imp...